A US academic medical center has registered a randomized, placebo-controlled trial of BPC-157 in patients recovering from shoulder surgery. The record went up on ClinicalTrials.gov on September 3, 2026 under identifier NCT07803250, with the University of Arkansas as lead sponsor and the University of Arkansas for Medical Sciences Medical Center in Little Rock as the listed site.
That is a meaningfully different kind of document from what has carried the BPC-157 conversation for thirty years. The compound's reputation rests almost entirely on rodent work out of a single research group, and the registry record says so in its own words: BPC-157 "has not undergone formal human clinical trials and remains an investigational compound not approved by the FDA." The trial is listed as not yet recruiting with a start date of January 1, 2027, so there is nothing to read into results — there are none. What there is to read is the protocol, and the protocol is unusually specific about what it intends to measure.
Research-context information only. This article reports on a publicly posted clinical trial registration and on published peer-reviewed literature. It is not medical advice, and nothing here is a recommendation to use, dose or discontinue any compound. BPC-157 is not approved by the FDA for any indication. Material sold through the research channel is research-use-only, is not manufactured or labeled to investigational-product standard, and has not been evaluated for safety, purity or potency as sold in that channel. A registered trial supplies its own drug product under institutional control; that is not the same material or the same oversight. Consult a licensed physician for personal medical decisions.
What the protocol actually specifies
The design is a randomized parallel-assignment pilot with quadruple masking — participant, care provider, investigator and outcomes assessor are all blinded. That is a stronger masking arrangement than most of the human BPC-157 literature, which consists largely of uncontrolled case series.
| Element | Detail as registered |
|---|---|
| Identifier | NCT07803250 |
| Lead sponsor | University of Arkansas (academic) |
| Site | UAMS Medical Center, Little Rock, United States |
| First posted | September 3, 2026 |
| Phase / status | Phase 1 · not yet recruiting |
| Listed start | January 1, 2027 |
| Primary completion | August 1, 2027 |
| Design | Randomized, parallel, quadruple-masked |
| Route | Subcutaneous, self-administered, once daily |
| Duration | 90 days following arthroscopic repair |
| Comparators | Matched daily saline injection; plus a described no-treatment control |
| Condition | Full-thickness posterosuperior rotator cuff tear under 2.5 cm |
One discrepancy is worth recording, because it will propagate into secondary coverage otherwise: the structured enrollment field lists 30 participants as an estimate, while the plain-language summary in the same record describes twenty patients being enrolled and randomized. Early-stage registry entries frequently carry that kind of internal drift and it usually resolves on a later update. Treat the enrollment figure as unsettled rather than quoting either number as final.
The endpoint choice is the interesting part
The registered primary outcome is not a questionnaire. It is isometric shoulder strength measured by handheld dynamometer — abduction and external rotation at zero degrees of abduction, three trials per measurement, captured at baseline, twelve weeks and five months after surgery.
Around that, the record describes MRI assessment of tendon healing, patient-reported outcome measures, range of motion, and blood sampling for biomarkers of collagen turnover and inflammation. So the protocol is set up to distinguish between three things that anecdotal reports routinely collapse together: whether the tendon structurally heals differently, whether measurable force production differs, and whether the person simply feels better.
The eligibility criteria narrow the population hard, which is appropriate for a pilot and limits what the result will generalize to. Participants must be 18 or older with a BMI between 20.0 and 34.9, carrying a pre-operative MRI-confirmed full-thickness posterosuperior tear under 2.5 cm in anteroposterior dimension, scheduled for arthroscopic repair with one of three named surgeons. Excluded are prior repairs on that shoulder, pregnancy or breastfeeding, any platelet-rich plasma or other biologic injection in that shoulder in the past twelve months, diabetes, autoimmune disease, active blood-borne infection, and — a detail that will matter to a good share of the audience reading about this compound — anyone who has undergone hormone replacement or testosterone replacement therapy in the last twelve months.
That last exclusion is a deliberate design choice rather than a safety warning. Both HRT and TRT independently affect collagen turnover and recovery, and with a cohort this small, allowing them in would make the tendon-healing signal unreadable.
What this does and does not change for buyers
It changes the evidence conversation and nothing about the product. Anyone comparing BPC-157 vendors today is buying research-use-only lyophilized material on exactly the terms that applied last week, and will be until at least the second half of 2027, when this pilot's primary completion date arrives.
What it does change is the quality of the argument available on both sides. The standing criticism of BPC-157 — no controlled human data — remains accurate today, but it now has an expiry date attached and a named institution behind it. The practical consequence for anyone tracking this compound is that the questions worth asking shift from whether a trial will ever happen to which endpoints it reports and whether the strength measurement separates from saline.
For anyone weighing the purchase decision itself, the variables that actually differ between sources are unchanged by this news: third-party COA coverage per batch, purity by HPLC with identity confirmed by mass spectrometry, price per milligram, and whether the vendor is shipping domestically. Those are covered in the BPC-157 buying guide, and current discount codes across recommended vendors are listed on the deals page.
